The microRNA-200 family - A potential diagnostic marker in hepatocellular carcinoma?

Journal of Surgical Oncology

Volumn 110, Issue 4, 2014, Pages 430-438

  Dhayat, Sameer A ^a   Mardin, Wolf A ^a   Köhler, Gabriele ^a   Bahde, Ralf ^a   Vowinkel, Thorsten ^a   Wolters, Heiner ^a   Senninger, Norbert ^a   Haier, Jörg ^a   Mees, Soeren T ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

hepatocellular carcinoma; liver cirrhosis; microRNA 200 family

Indexed keywords

MICRORNA 200; TRANSCRIPTION FACTOR ZEB1; UVOMORULIN; VIMENTIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

HEPATOCELLULAR CARCINOMA; LIVER CIRRHOSIS; MICRORNA-200 FAMILY;

ADULT; AGED; AGED, 80 AND OVER; CADHERINS; CARCINOMA, HEPATOCELLULAR; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84905757161     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23668     Document Type: Article

References (33)

1. Nordenstedt H, White DL, El-Serag HB:, The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 2010; 42: S206-S214.
2. Farazi PA, DePinho RA:, Hepatocellular carcinoma pathogenesis: From genes to environment. Nat Rev Cancer 2006; 6: 674-687.
3. Aravalli RN, Steer CJ, Cressman EN:, Molecular mechanisms of hepatocellular carcinoma. Hepatology 2008; 48: 2047-2063.
4. Llovet JM, Ricci S, Mazzaferro V, et al.: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
5. Leong TY, Leong AS:, Epidemiology and carcinogenesis of hepatocellular carcinoma. HPB (Oxford) 2005; 7: 5-15.
6. Bruix J, Sherman M:, Management of hepatocellular carcinoma: An update. Hepatology 2011; 53: 1020-1022.
7. Jiang J, Gusev Y, Aderca I, et al.: Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res 2008; 14: 419-427.
8. Huang YS, Dai Y, Yu XF, et al.: Microarray analysis of microRNA expression in hepatocellular carcinoma and non-tumorous tissues without viral hepatitis. J Gastroenterol Hepatol 2008; 23: 87-94.
9. Huang XH, Wang Q, Chen JS, et al.: Bead-based microarray analysis of microRNA expression in hepatocellular carcinoma: miR-338 is downregulated. Hepatol Res 2009; 39: 786-794.
10. Ji J, Wang XW:, New kids on the block: Diagnostic and prognostic microRNAs in hepatocellular carcinoma. Cancer Biol Ther 2009; 8: 1686-1693.
11. Hung CS, Liu HH, Liu JJ, et al.: MicroRNA-200a and -200b mediated hepatocellular carcinoma cell migration through the epithelial to mesenchymal transition markers. Ann Surg Oncol 2013; 20: S360-S368.
12. Murakami Y, Toyoda H, Tanaka M, et al.: The progression of liver fibrosis is related with overexpression of the miR-199 and 200 families. PLoS ONE 2011; 6: e16081.
13. Murakami Y, Yasuda T, Saigo K, et al.: Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 2006; 25: 2537-2545.
14. Korpal M, Kang Y:, The emerging role of miR-200 family of microRNAs in epithelial-mesenchymal transition and cancer metastasis. RNA Biol 2008; 5: 115-119.
15. Greenburg G, Hay ED:, Epithelia suspended in collagen gels can lose polarity and express characteristics of migrating mesenchymal cells. J Cell Biol 1982; 95: 333-339.
16. Batts KP, Ludwig J:, Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995; 19: 1409-1417.
17. Salvi A, Abeni E, Portolani N, et al.: Human hepatocellular carcinoma cell-specific miRNAs reveal the differential expression of miR-24 and miR-27a in cirrhotic/non-cirrhotic HCC. Int J Oncol 2013; 42: 391-402.
18. Budhu A, Jia HL, Forgues M, et al.: Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 2008; 47: 897-907.
19. Livak KJ, Schmittgen TD:, Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402-408.
20. Hsu SM, Raine L, Fanger H:, A comparative study of the peroxidase-antiperoxidase method and an avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am J Clin Pathol 1981; 75: 734-738.
21. Debruyne EN, Delanghe JR:, Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: New aspects and applications. Clin Chim Acta 2008; 395: 19-26.
22. EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-943.
23. Abu El Makarem M:, An overview of biomarkers for the diagnosis of hepatocellular carcinoma. Hepat Mon 2012; 12: e6122.
24. Malaguarnera G, Giordano M, Paladina I, et al.: Serum markers of hepatocellular carcinoma. Dig Dis Sci 2010; 55: 2744-2755.
25. Gregory PA, Bracken CP, Smith E, et al.: An autocrine TGF-beta/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Mol Biol Cell 2011; 22: 1686-1698.
26. Park SM, Gaur AB, Lengyel E, et al.: The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008; 22: 894-907.
27. Korpal M, Lee ES, Hu G, et al.: The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008; 283: 14910-14914.
28. Cochrane DR, Howe EN, Spoelstra NS, et al.: Loss of miR-200c: A marker of aggressiveness and chemoresistance in female reproductive cancers. J Oncol 2010; 2010: 821717.
29. Li Y, VandenBoom TG 2nd, Kong D, et al.: Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 2009; 69: 6704-6712.
30. Tryndyak VP, Beland FA, Pogribny IP:, E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells. Int J Cancer 2010; 126: 2575-2583.
31. Adam L, Zhong M, Choi W, et al.: miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res 2009; 15: 5060-5072.
32. Kong D, Li Y, Wang Z, et al.: miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells. Stem Cells 2009; 27: 1712-1721.
33. Smith CM, Watson DI, Leong MP, et al.: miR-200 family expression is downregulated upon neoplastic progression of Barrett's esophagus. World J Gastroenterol 2011; 17: 1036-1044.